<DOC>
	<DOCNO>NCT02107937</DOCNO>
	<brief_summary>The purpose study determine whether DCVAC/OvCa add chemotherapy ( carboplatin plus paclitaxel first line chemotherapy ) may result prolongation progression free survival ( PFS ) .</brief_summary>
	<brief_title>Phase II Study DCVAC/OvCa Added First Line Carboplatin Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma</brief_title>
	<detailed_description>The purpose study determine whether DCVAC/OvCa add Standard Care chemotherapy ( carboplatin plus paclitaxel first line chemotherapy ) may result prolongation progression free survival ( PFS ) .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Female age â‰¥18 year Patients newly diagnose , histologically confirm , International Federation Gynecology Obstetrics ( FIGO ) stage III epithelial ovarian , primary peritoneal fallopian tube carcinoma ( serous , endometrioid mucinous ) undergone initial surgery 3 week randomization select receive first line Standard Care chemotherapy ( optional prolongation 6 week surgery ) Optimally debulked ( zero residuum ) maximal residuum &lt; 1cm Eastern Cooperative Oncology Group ( ECOG ) Performance status 0,1,2 FIGO I , II , IV epithelial ovarian cancer FIGO III clear cell epithelial ovarian cancer Nonepithelial ovarian cancer ( OvCa ) , borderline tumor ( tumor low malignant potential ) Postsurgery residual disease lesion ( ) &gt; 1cm Prior current systemic anticancer therapy ovarian cancer [ example chemotherapy , monoclonal antibody therapy ( bevacizumab ) , tyrosine kinase inhibitor therapy , vascular endothelial growth factor ( VEGF ) therapy hormonal therapy ] Previous concurrent radiotherapy abdomen pelvis Malignancy epithelial ovarian cancer , except clinical remission ( CR ) minimum 3 year , except carcinoma insitu cervix nonmelanoma skin carcinoma Patient comorbidities : Human immunodeficiency virus ( HIV ) positive , human Tlymphotropic virus ( HTLV ) positive , Active hepatitis B ( HBV ) , active hepatitis C ( HCV ) , active syphilis Evidence active bacterial , viral fungal infection require systemic treatment Clinically significant cardiovascular disease include : Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia require medication Uncontrolled hypertension Myocardial infarction ventricular arrhythmia stroke within 6 month period inclusion , ejection fraction ( EF ) &lt; 40 percent serious cardiac conduction system disorder , pacemaker present</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>serous</keyword>
	<keyword>endometrioid</keyword>
	<keyword>mucinous</keyword>
	<keyword>epithelial ovarian cancer</keyword>
</DOC>